Brought to you by 
Parke-Davis gets rights to GenVec's BioByPass product
04 Feb 2002
Executive Summary
Private gene therapy company GenVec entered into a possible $100mm deal to develop BioByPass, its angiogenesis product for Warner Lambert's Parke-Davis division. In return, Parke-Davis gets exclusive worldwide marketing rights outside Asia.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Gene Therapy, Cell Therapy
- Large Molecule
Deal Status
- Terminated
Deal Type
-
Alliance
- Co-Promotion
- Includes Contract
- Includes Equity
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Parke-Davis gets rights to GenVec's BioByPass product
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice